Jannsen’s Tremfya becomes first FDA-approved IL-23 inhibitor for active psoriatic arthritis
pharmafile | July 15, 2020 | News story | Research and Development, Sales and Marketing | FDA, Jannsen, Tremfya, active psoriatic arthritis
Janssen has reported that its therapy Tremfya (guselkumab) has become the first selective interleukin (IL)-23 inhibitor approved by the FDA for the treatment of active psoriatic arthritis.
Data from two Phase 3 trials submitted in support of the regulatory decision confirmed that 52% and 64% of patients receiving Tremfya across both trials had achieved an ACR20 response, representing an improvement of 20% in symptoms as measured by the American College of Rheumatology (ACR) scale – the primary endpoint of both studies. This was compared to 22% and 33% in those receiving placebo.
It was also reported that the therapy improved patient symptoms when measured against the Health Assessment Questionnaire Disease Index and SF-36 Physical Component Summary score, including soft tissue pain and inflammation of the extremities.
“Psoriatic arthritis is a complex multi-faceted disease and, for many patients, additional biologic options are very much needed,” commented Dr Philip J Measei, Lead Study Investigator on one of the studies as well as Director of Rheumatology Research at the Swedish Medical Center/Providence St Joseph Health and Clinical Professor at the University of Washington School of Medicine. “The two Phase 3 pivotal trials evaluating the safety and efficacy of Tremfya, an IL-23 inhibitor, for the treatment of adults with active psoriatic arthritis provided insight into how it can improve joint symptoms.”
Matt Fellows
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …
FDA approves Moderna’s updated COVID-19 vaccines targeting new variant
The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and …
